Luminex Corporation has announced it has entered into a nonbinding letter of intent to divest its Rules-Based Medicine research and development project (“RBM”) to a newly formed company to be headed by Dr. Mark B. Chandler, Luminex’s current Chairman, President and Chief Executive Officer. RBM uses the Luminex xMAP(TM) technology to analyze a large number Read more about Luminex Announces Letter Of Intent To Sell RBM[…]